Reported about 17 hours ago
Novo Nordisk anticipates a recovery in sales of its Wegovy weight-loss drug in the U.S. following a ban on compounded copies, despite recent declines in prescription growth. The company has adjusted its 2025 sales growth forecast due to increased market competition. CEO Lars Fruergaard Jorgensen expressed hopes for improved sales as supply constraints are alleviated, although concerns remain regarding the impact of compounded medications on overall market share.
Source: YAHOO